This preclinical breakthrough enhances RVMD's RAS-targeted pipeline differentiation; traders should monitor upcoming clinical trial initiations for RM-055 and combination strategies. The mechanism's potential to overcome resistance could re-rate the stock if clinical data validates preclinical results.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $141.50entry
- T+1 · 7mo ago −4.96%α −4.57% · $134.48
- T+5 · 7mo ago −0.49%α −0.55% · $140.80
- T+20 · 6mo ago +4.10%α +0.93% · $147.30
- T+60 · 4mo ago +31.56%α +26.78% · $186.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced preclinical data for RM-055, a novel oral catalytic RAS(ON) inhibitor, showing deep and durable tumor regressions in KRAS G12-mutant cancer models, including tumors resistant to prior RAS inhibitors. The data were presented at the AACR Annual Meeting on April 21, 2026.
Key Facts
- Revolution Medicines disclosed preclinical data for RM-055, a new class of mutant-targeted catalytic RAS(ON) inhibitors.
- RM-055 demonstrated robust antitumor activity in KRAS G12-mutant xenograft models of pancreatic, lung, and colorectal cancers.
- Tumors resistant to prior RAS inhibitors responded to RM-055, suggesting potential to overcome acquired resistance.
- The compound promotes conversion of mutant RAS(ON) to RAS(OFF), mimicking natural regulation and offering a differentiated mechanism.
- RM-055 showed preferential suppression of RAS pathway activation in tumors over normal tissues, indicating a potential therapeutic window.
Financial Impact
No direct financial impact disclosed; preclinical stage with future commercial potential in high-prevalence RAS-mutant cancers.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- Development timeline and regulatory path for RM-055 remain uncertain.
- Competitive RAS inhibitor landscape is rapidly evolving with multiple late-stage candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278567 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers